Iovance Biotherapeutics Inc(IOVA)stock report

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Pipelines: https://www.iovance.com/clinical/pipeline/
Phase II stage

Finance:
Q3 2019(9/30/19): Cash 404M. Loss 47.55M

EPS and Sales:
https://finance.yahoo.com/quote/IOVA/financials?p=IOVA

Date EPS % last year % last quarter
 2018.9.30 -1.01 4.72% -38.61%
2018.12.31 -1.27 9.93% -25.74%
 2019.3.31 -0.3 3.23% 76.38%
2019.6.30 -0.68 -10.97% -126.67%

Sale:0

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=IOVA&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/IOVA/institutional-ownership/

2019.12.10:
Total institutions: 197,no change
Shares hold: 125000k shares. no change
shares% hold: 98.98%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/IOVA/price-targe

Leave a Reply